ΚΑΡΔΙΟΓΕΝΕΣ ΠΝΕΥΜΟΝΙΚΟ ΟΙΔΗΜΑ

ΙΩΑΝΝΗΣ ΑΛΕΞΑΝΙΑΝ MD, PhD

Επιμελητής Καρδιολόγος

Καρδιολογική κλινική ΓΝΑ «Ο Ευαγγελισμός»

Normal Heart




pressure (Kpa)
16
12
8
4
3
2
1
4
0.2
0.4
0.6
0.8
1.0
1.2
1.4
time (s)
A.S
V.S
V.D
A.S
V.S
V.D
aorta
left ventricle
left atrium
Extend Page



A = operating point for non-failing heart
B = operating point for failing heart
C = effects of a diuretic or venodilator
D = effects of mixed vasodilator or inotropic drug

Gas exchange between alveoli and capillaries



Gases can dissolve & diffuse between the lungs and the circulatory system

Alveoli and Pulmonary Capillaries

The pulmonary **arteries** carry blood which is low in oxygen from the heart to the lungs.

These blood vessels branch repeatedly, eventually forming dense networks of **capillaries** that completely surround each alveolus.

Oxygen and carbon dioxide are exchanged between the air in the **alveoli** and the blood in the pulmonary capillaries.

Blood leaves the capillaries via the pulmonary **veins**, which transport oxygenated blood back to the heart.




Cardiac output
Heart rate
Stroke volume
Preload
Contractility
Afterload


Factors Affecting Heart Rate (HR)
Autonomic innervation
Hormones
Fitness levels
Age
Factors Affecting Stroke Volume (SV)
Heart size
Fitness levels
Gender
Contractility
Duration of contraction
Preload (EDV)
Afterload (resistance)
Heart Rate (HR)
Stroke Volume (SV) = EDV – ESV
Cardiac Output (CO) = HR × SV

Ejection Fraction




Diastole (relaxation)
Systole (contraction)
(A) Normal
Right atrium
Left atrium
Right ventricle
Left ventricle
Aorta
(B) Systolic dysfunction
Enlarged ventricles
(C) Diastolic dysfunction
Thickening of the ventricular muscle

Definition of heart failure with preserved (HFpEF), mid-range (HFmrEF) and reduced ejection fraction (HFrEF)

Type of HF		HFrEF	HFmrEF	HFpEF
CRITERIA	1	Symptoms ± Signs[a]	Symptoms ± Signs[a]	Symptoms ± Signs[a]
	2	LVEF <40%	LVEF 40–49%	LVEF ≥50%
	3	–	1. Elevated levels of natriuretic peptides[b]; 2. At least one additional criterion: a. relevant structural heart disease (LVH and/or LAE), b. diastolic dysfunction (for details see Section 4.3.2).	1. Elevated levels of natriuretic peptides[b]; 2. At least one additional criterion: a. relevant structural heart disease (LVH and/or LAE), b. diastolic dysfunction (for details see Section 4.3.2).

- Left atrial volume index (LAVI) >34 mL/m2 or a left ventricular mass index (LVMI) ≥115 g/m2 for males and ≥95 g/m2 for females.
- Functional alterations are an E/e' ≥13 and a mean e' septal and lateral wall <9 cm

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure



Edema (swelling) of the ankles and feet


Shortness of breath
Swelling of feet & legs
Chronic lack of energy
Difficulty sleeping at night due to breathing problems
Swollen or tender abdomen with loss of appetite
Cough with frothy Sputum
Increased urination at night
Confusion and/or impaired memory


Right heart failure
Left heart failure
Congestion of peripheral tissues
Decreased cardiac output
Pulmonary congestion
Dependent edema and ascites
Liver congestion
GI tract congestion
Signs related to impaired liver function
Anorexia, GI distress, weight loss
Activity intolerance and signs of decreased tissue perfusion
Impaired gas exchange
Pulmonary edema
Cyanosis and signs of hypoxia
Orthopnea
Cough with frothy sputum
Paroxysmal nocturnal dyspnea


R

Common Chest X-ray abnormalities in HF

- Cardiomegaly
- Ventricular hypertrophy
- Pulmonary venous congestion
- Interstitial oedema
- Pleural effusions
- Kerley B lines

Laboratory tests abnormalities in HF

- Creatinine↑
- BUN↑
- Anaemia
- Na
- K ↑
- Glu
- BNP / NT-proBNP ↑
- Albumin
- AST/ALT ↑
- Troponin ↑
- Thyroid tests
- Urinalysis
- INR
- CRP ↑
- WBC↑

New York Heart Association (NYHA) functional classification based on severity of symptoms and physical activity

Class I	No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.
Class II	Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.
Class III	Marked limitation of physical activity. Comfortable at rest, but less than ordinary physical activity results in undue breathlessness, fatigue, or palpitations.
Class IV	Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort is increased.

AETIOLOGIES OF HEART FAILURE

DISEASED MYOCARDIUM		
Ischaemic heart disease	Myocardial scar	
	Myocardial stunning/hibernation	
	Epicardial coronary artery disease	
	Abnormal coronary microcirculation	
	Endothelial dysfunction	
Toxic damage	Recreational substance abuse	Alcohol, cocaine, amphetamine, anabolic steroids.
	Heavy metals	Copper, iron, lead, cobalt.
	Medications	Cytostatic drugs (e.g. anthracyclines), immunomodulating drugs (e.g. interferons monoclonal antibodies such as trastuzumab, cetuximab), antidepressant drugs, antiarrhythmics, non-steroidal anti-inflammatory drugs, anaesthetics.
	Radiation	
Immune-mediated and inflammatory damage	Related to infection	Bacteria, spirochaetes, fungi, protozoa, parasites (Chagas disease), rickettsiae, viruses (HIV/AIDS).
	Not related to infection	Lymphocytic/giant cell myocarditis, autoimmune diseases (e.g. Graves' disease, rheumatoid arthritis, connective tissue disorders, mainly systemic lupus erythematosus), hypersensitivity and eosinophilic myocarditis (Churg–Strauss).
Infiltration	Related to malignancy	Direct infiltrations and metastases.
	Not related to malignancy	Amyloidosis, sarcoidosis, haemochromatosis (iron), glycogen storage diseases (e.g. Pompe disease), lysosomal storage diseases (e.g. Fabry disease).
Metabolic derangements	Hormonal	Thyroid diseases, parathyroid diseases, acromegaly, GH deficiency, hypercortisolaemia, Conn's disease, Addison disease, diabetes, metabolic syndrome, phaeochromocytoma, pathologies related to pregnancy and peripartum.
	Nutritional	Deficiencies in thiamine, L-carnitine, selenium, iron, phosphates, calcium, complex malnutrition (e.g. malignancy, AIDS, anorexia nervosa), obesity.
Genetic abnormalities	Diverse forms	HCM, DCM, LV non-compaction, ARVC, restrictive cardiomyopathy (for details see respective expert documents), muscular dystrophies and laminopathies.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

AETIOLOGIES OF HEART FAILURE

ABNORMAL LOADING CONDITIONS		
Hypertension		
Valve and myocardium structural defects	Acquired	Mitral, aortic, tricuspid and pulmonary valve diseases.
	Congenital	Atrial and ventricular septum defects and others (for details see a respective expert document).
Pericardial and endomyocardial pathologies	Pericardial	Constrictive pericarditis Pericardial effusion
	Endomyocardial	HES, EMF, endocardial fibroelastosis.
High output states		Severe anaemia, sepsis, thyrotoxicosis, Paget's disease, arteriovenous fistula, pregnancy.
Volume overload		Renal failure, iatrogenic fluid overload.
ARRHYTHMIAS		
Tachyarrhythmias		Atrial, ventricular arrhythmias.
Bradyarrhythmias		Sinus node dysfunctions, conduction disorders.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

DIAGNOSTIC ALGORITHM FOR A DIAGNOSIS OF HEART FAILURE



2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure



Key: ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide; NP = natriuretic peptide; RAAS = renin–angiotensin–aldosterone system; SNS = sympathetic nervous system

Adapted from Kalra *et al.*[6]

THERAPEUTIC ALGORITHM FOR A PATIENT WITH SYMPTOMATIC HFREF



2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Evidence-based doses of disease-modifying drugs in key randomized trials in HFREF

	Starting dose (mg)	Target dose (mg)
ACE-I		
Captopril[a]	6.25 *t.i.d.*	50 *t.i.d.*
Enalapril	2.5 *b.i.d.*	20 *b.i.d.*
Lisinopril[b]	2.5–5.0 *o.d.*	20–35 *o.d.*
Ramipril	2.5 o.d.	10 *o.d.*
Trandolapril[a]	0.5 *o.d.*	4 *o.d.*
Beta-blockers		
Bisoprolol	1.25 *o.d.*	10 *o.d.*
Carvedilol	3.125 *b.i.d.*	25 *b.i.d.*[d]
Metoprolol succinate (CR/XL)	12.5–25 *o.d.*	200 o.d.
Nebivolol[c]	1.25 *o.d.*	10 *o.d.*
ARBs		
Candesartan	4–8 *o.d.*	32 *o.d.*
Valsartan	40 *b.i.d.*	160 *b.i.d.*
Losartan[b,c]	50 *o.d.*	150 *o.d.*
MRAs		
Eplerenone	25 *o.d.*	50 *o.d.*
Spironolactone	25 *o.d.*	50 *o.d.*
ARNI		
Sacubitril/valsartan	49/51 *b.i.d.*	97/103 *b.i.d.*
I_f-channel blocker		
Ivabradine	5 *b.i.d.*	7.5 *b.i.d.*

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

ACUTE HEART FAILURE

HEART FAILURE–ASSOCIATED HOSPITALIZATIONS IN THE UNITED STATES





J Am Coll Cardiol 2013;61:1259–67

DEFINITION OF ACUTE HF

- **AHF refers to rapid onset or worsening of symptoms and/or signs of HF.**

- It is a life-threatening medical condition requiring urgent evaluation and treatment, typically leading to urgent hospital admission.

- AHF may present as a first occurrence (**de novo**) or, more frequently, as a consequence of **acute decompensation of chronic HF**, and may be caused by primary cardiac dysfunction or precipitated by extrinsic factors, often in patients with chronic HF

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure



- acute decompensation of chronic HF
- de novo AHF
- End-stage HF

IN-HOSPITAL MORTALITY



30-DAY MORTALITY



Canadian Journal of Cardiology 30 (2014) 312e319

FACTORS TRIGGERING ACUTE HEART FAILURE

Acute coronary syndrome.
Tachyarrhythmia (e.g. atrial fibrillation, ventricular tachycardia).
Excessive rise in blood pressure.
Infection (e.g. pneumonia, infective endocarditis, sepsis).
Non-adherence with salt/fluid intake or medications.
Bradyarrhythmia.
Toxic substances (alcohol, recreational drugs).
Drugs (e.g. NSAIDs, corticosteroids, negative inotropic substances, cardiotoxic chemotherapeutics).
Exacerbation of chronic obstructive pulmonary disease.
Pulmonary embolism.
Surgery and perioperative complications.
Increased sympathetic drive, stress-related cardiomyopathy.
Metabolic/hormonal derangements (e.g. thyroid dysfunction, diabetic ketosis, adrenal dysfunction, pregnancy and peripartum related abnormalities).
Cerebrovascular insult.
Acute mechanical cause: myocardial rupture complicating ACS (free wall rupture, ventricular septal defect, acute mitral regurgitation), chest trauma or cardiac intervention, acute native or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

NATURAL HISTORY OF ADHF

effects of repeated hospitalizations on cardiac function over time



With each successive hospitalization, myocardial damage may occur secondary to disease progression and untoward effects of therapies (e.g., currently available inotropes) resulting in decreased coronary perfusion.

Am J Cardiol 96(6A): 11G–17G

$$\dot{Q}_f = K_f[(P_c - P_{is}) - \sigma(\pi_{pl} - \pi_{is})] \times A$$

where $\dot{Q}_f$ = net flow of fluid

K_f = capillary filtration coefficient; this describes the permeability characteristics of the membrane to fluids

P_c = capillary hydrostatic pressure

P_{is} = hydrostatic pressure of the interstitial fluid

σ = reflection coefficient; this describes the ability of the membrane to prevent extravasation of solute particles

π_{pl} = colloid osmotic (oncotic) pressure of the plasma

π_{is} = colloid osmotic pressure of the interstitial fluid

A = the surface area of the alveolar-capillary barrier



Fluid exits capillary since capillary hydrostatic pressure (35 mm Hg) is greater than blood colloidal osmotic pressure (25 mm Hg)

No net movement of fluid since capillary hydrostatic pressure (25 mm Hg) = blood colloidal osmotic pressure (25 mm Hg)

Fluid re-enters capillary since capillary hydrostatic pressure (18 mm Hg) is less than blood colloidal osmotic pressure (25 mm Hg)



Source: Michael R. Foley, Thomas H. Strong, Jr., Thomas J. Garite: Obstetric Intensive Care Manual, 4th Ed.
www.obgyn.mhmedical.com

Table 1. Hemodynamic monitoring with a pulmonary artery catheter: Normal pressures and resistance values.[27]

	Mean	Range
Right atrium	3 mm Hg	1–5 mm Hg
Right ventricle		
Peak-systolic	25 mm Hg	15–30 mm Hg
End-diastolic	9 mm Hg	4–12 mm Hg
Pulmonary capillary wedge pressure	9 mm Hg	4–12 mm Hg
Systemic vascular resistance	1100 dyne-sec·cm^{-5}	700–1600 dyne-sec·cm^{-5}
Pulmonary vascular resistance	70 dyne-sec·cm^{-5}	20–130 dyne-sec·cm^{-5}

Hemodynamics of Shock

LearnTheHeart.com

Red arrow indicates primary abnormality	PCWP (preload)	Cardiac Output	SVR (afterload)	Treatment
Hypovolemic shock	↓	↑	↑	IV fluids
Cardiogenic shock	↑	↓	↑	Inotropes Revascularization
Distributive shock (septic, neurogenic)	↓	↑	↓	Pressors IV fluids

PCWP = pulmonary capillary wedge pressure SVR = systemic vascular resistance

Figure 1: Illustration of Pressure-dependent- and Pressure-independent Mechanisms Responsible for Pulmonary Oedema Formation and Resolution



Acute increase in afterload increases fluid transfer across alveolo-capillary membrane. Alveolar epithelial cells are involved in fluid formation and fluid clearance by regulation of sodium and chloride transfer via active signalling processes. Pulmonary oedema resolution depends on active sodium reabsorption as well as on capacity of intact lymphatics to drain fluids out of alveoli into systemic veins. LVEDP = left ventricular end diastolic pressure; PCWP = pulmonary capillary wedge pressure; SV = stroke volume.


Normal bronchiole
and alveoli
Pneumonia causes
an accumulation
of fluid in the alveoli
wiseGEEK



Ware et al. NEJM 2005

Mechanisms of edema formation

CAUSE	EXAMPLE
↑ P_c	Increased capillary pressure (failure of venous pumps, heart failure)
↓ π_c	Decreased plasma protein osmotic pressure (severe liver failure, nephrotic syndrome)
↑ π_i	Increased capillary protein permeability (due to release of vasoactive substances) (e.g. burns, trauma, infection)
Impaired Lymphatic drainage	parasitic infection of lymph nodes (filariasis)


Increased permeability (ARDS)
Low 50% plasma protein osmotic pressure
High pulmonary capillary hydrostatic pressure (cardiogenic pulmonary edema)
Pulmonary Extravascular Water (mL)
1600
1200
800
400
0
10
20
30
40
Pulmonary Artery Wedge Pressure (PWP) (mm Hg)

Non-cardiogenic and Cardiogenic Pulmonary Edema

- Non-cardiogenic pulmonary edema (ARDS)
  - Pulmonary or systemic insult to the alveolar-capillary unit with release of inflammatory mediators
  - Intubate if hypoxemia is refractory to high inspired oxygen concentrations
- Cardiogenic pulmonary edema
  - Elevated pulmonary capillary pressure results in fluid accumulation in lung interstitium
  - Ventilatory support
  - Support cardiovascular function
    - Preload reduction
    - Afterload reduction
    - Decrease myocardial metabolic demand


↓Ventricular emptying
↓Ventricular relaxation
↓Cardiac output
↑ EDV / pressure
↑ LA pressure
↑ Pulmonary vascular pressure
↑ Hydrostatic pressure > oncotic pressure
and lympahatic drainage
Fluid accumulates in the intersitium +/- alveoli
↓ Gas Exchange
↑ Hypoxia
↑ Work of breathing
↑ Catecholamine release
↑ Renin, angiotensin,
aldosterone activation
↑Systemic vascular resistance
↑Preload & afterload
↑Cardiac work and O2 demand


Pulmonary Hypertension
Pulmonary Vasoconstriction
Systemic Vasodilatation
Acute Hypoxia
Peripheral Chemoreceptor
Cold, Exercise
Ventilation ↑
Sympathetic Activation
Respiratory Alkalosis
Heart Rate ↑
Cardiac Output ↑
Blood Pressure ↑
Myocardial contraction Velocity ↑
Inhibition

Clinical profiles of patients with acute HF based on the presence/absence of congestion and/or hypoperfusion



2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Initial management of a patient with acute heart failure



2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

The diagnostic workup in AHF

It is recommended that initial diagnosis of AHF should be based on a thorough history assessing symptoms, prior cardiovascular history and potential cardiac and non-cardiac precipitants, as well as on the assessment of signs/symptoms of congestion and/or hypoperfusion by physical examination and further confirmed by appropriate additional investigations such as ECG, chest X-ray, laboratory assessment (with specific biomarkers) and echocardiography.

Upon presentation to the ED or CCU/ICU, a plasma **NP level (BNP, NT-proBNP or MR-proANP)** should be measured in all patients with acute dyspnea and suspected AHF to help in the differentiation of AHF from non-cardiac causes of acute dyspnea. NPs have high sensitivity, and normal levels in patients with suspected AHF makes the diagnosis unlikely (thresholds:

- **BNP <100 pg/mL**
- **NT-proBNP <300 pg/mL**
- **MR-proANP <120 pg/mL**

Assessment of **procalcitonin** levels may be considered in patients with AHF with suspected coexisting infection, particularly for the differential diagnosis of pneumonia and to guide antibiotic therapy

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

regarding monitoring of clinical status of patients hospitalized due to acute heart failure

Recommendations	Class	Level
Standard non-invasive monitoring of heart rate, rhythm, respiratory rate, oxygen saturation and blood pressure is recommended.	I	C
It is recommended that patients should be weighed daily and have an accurate fluid balance chart completed.	I	C
It is recommended to evaluate signs and symptoms relevant to HF (e.g. dyspnoea, pulmonary rales, peripheral oedema, weight) daily to assess correction of fluid overload.	I	C
Frequent, often daily, measurement of renal function (blood urea, creatinine) and electrolytes (potassium, sodium) during i.v. therapy and when renin-angiotensin-aldosterone system antagonists are initiated is recommended.	I	C
Intra-arterial line should be considered in patients with hypotension and persistent symptoms despite treatment.	IIa	C
Pulmonary artery catheter may be considered in patients who, despite pharmacological treatment present refractory symptoms (particularly with hypotension and hypoperfusion).	IIb	C

European Heart Journal (2016) **37**, 2129-2200 - doi:10.1093/eurheartj/ehw 128

NT-proBNP Predicts Outcome After Hospital Discharge in Heart Failure Patients

6-month death or readmission

TABLE 4. Multivariate
Predictors of Death and
Discharge From Index H

Age	3)
NYHA class at discharge III/I	4)
Volume overload at discharge	
Change in NT-proBNP (vs de	
Change <30%	7)
Increase ≥30%	7)





Circulation. 2004;110:2168-2174

Transpulmonary thermodilution-PICCO

and Edward / Volume ViewTM



Schematic image of the PICCOplus setup.
Allocation of the CVC lumen, CVP measurement and positioning of the stopcocks are subject to adaption to individual circumstances.

Parameters Measured with the PiCCO-Technology

Thermodilution parameters	
Cardiac output	CO
Global end-diastolic volume	GEDV
Intrathoracic blood volum	ITBV
Extravascular lung water	EVLW
Pulmonary vascular permeability index	PVPI
Cardiac function index	CFI
Global ejection fraction	GEF
Pulse contour parameters	
Pulse contour cardiac output	PCCO
Arterial blood pressure	AP
Heart rate	HR
Stroke volume	SV
Stroke volume variation	SVV
Pulse pressure variation	PPV
Systemic vascular resistance	SVR
Index of left ventricular contractility	dPmx

Yonsei Med J. 2010 May 1; 51(3): 354–359.



- **Extra vascular lung water index (ELWI)**
- **Pulmonary vascular permeability index (PVPI)**

Yonsei Med J. 2010 May 1; 51(3): 354–359.

THERAPY OF ACUTE HEART FAILURE

CONVENTIONAL TREATMENTS OF ACUTE HEART FAILURE

IV Diuretics

Reduce Volume Overload

Loop Diuretics

Vasodilators

Decrease Preload and Afterload

Nitroglycerin
Nitroprusside
Nesiritide

Inotropes

Augment Contractility

Dobutamine
Levosimendan
Milrinone

Fonarow GC. *Rev Cardiovasc Med.* 2001;2(suppl 2):S7–S12.



A = operating point for non-failing heart
B = operating point for failing heart
C = effects of a diuretic or venodilator
D = effects of mixed vasodilator or inotropic drug

MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE BASED ON CLINICAL PROFILE DURING AN EARLY PHASE



2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure



Doses of diuretics commonly used in patients with heart failure

Diuretics	Initial dose (mg)		Usual daily dose (mg)	
Loop diuretics[a]				
Furosemide	20–40		40–240	
Bumetanide	0.5–1.0		1–5	
Torasemide	5–10		10–20	
Thiazides[b]				
Bendroflumethiazide	2.5		2.5–10	
Hydrochlorothiazide	25		12.5–100	
Metolazone	2.5		2.5–10	
Indapamide[c]	2.5		2.5–5	
Potassium-sparing diuretics[d]				
	+ACE-I/ ARB	-ACE-I/ ARB	+ACE-I/ ARB	-ACE-I/ ARB
Spironolactone/ eplerenone	12.5–25	50	50	100–200
Amiloride	2.5	5	5–10	10–20
Triamterene	25	50	100	200

INTRAVENOUS VASODILATORS USED TO TREAT ACUTE HEART FAILURE

Vasodilator	Dosing	Main side effects	Other
Nitroglycerine	Start with10–20 µg/min, increase up to 200 µg/min	Hypotension, headache	Tolerance on continuous use
Isosorbide dinitrate	Start with 1 mg/h, increase up to 10 mg/h	Hypotension, headache	Tolerance on continuous use
Nitroprusside	Start with 0.3 µg/kg/min and increase up to 5 µg/kg/min	Hypotension, isocyanate toxicity	Light sensitive
Nesiritide[a]	Bolus 2 µg/kg + infusion 0.01 µg/kg/min	Hypotension	

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Mechanism of nitrates



Established and investigational inotropic agents

Inotropic mechanism	Drugs
Currently used	
Sodium-potassium-ATPase inhibition	Digoxin
Beta-Adrenoceptor stimulation	Dobutamine, dopamine
Phosphodiesterase inhibition	Enoximone, milrinone
Calcium sensitization	Levosimendan
Investigational	
Sodium-potassium-ATPase inhibition plus SERCA activation	Istaroxime
Acto-myosin cross-bridge activation	Omecamtiv mecarbil
SERCA activation	Gene transfer
SERCA activation plus vasodilation	Nitroxyl donor; CXL-1020
Ryanodine receptor stabilization	Ryanodine receptor stabilizer; S44121
Energetic modulation	Etomoxir, pyruvate

Eur Heart J, 2011:32;1838–1845

Mechanism of Action and Hemodynamic Effects of Common Vasoactive Medications in CS

Medication	Usual Infusion Dose	Receptor Binding				Hemodynamic Effects
		α_1	β_1	β_2	Dopamine	
Vasopressor/inotropes						
Dopamine	0.5–2 μg·kg^{-1}·min^{-1}	–	+	–	+++	↑CO
	5–10 μg·kg^{-1}·min^{-1}	+	+++	+	++	↑↑CO, ↑SVR
	10–20 μg·kg^{-1}·min^{-1}	+++	++	–	++	↑↑SVR, ↑CO
Norepinephrine	0.05–0.4 μg·kg^{-1}·min^{-1}	++++	++	+	–	↑↑SVR, ↑CO
Epinephrine	0.01–0.5 μg·kg^{-1}·min^{-1}	++++	++++	+++	–	↑↑CO, ↑↑SVR
Phenylephrine	0.1–10 μg·kg^{-1}·min^{-1}	+++	–	–	–	↑↑SVR
Vasopressin	0.02–0.04 U/min	Stimulates V_1 receptors in vascular smooth muscle				↑↑SVR, ↔PVR
Inodilators						
Dobutamine	2.5–20 μg·kg^{-1}·min^{-1}	+	++++	++	–	↑↑CO, ↓SVR, ↓PVR
Isoproterenol	2.0–20 μg/min	–	++++	+++	–	↑↑CO, ↓SVR, ↓PVR
Milrinone	0.125–0.75 μg·kg^{-1}·min^{-1}	PD-3 inhibitor				↑CO, ↓SVR, ↓PVR
Enoximone	2–10 μg·kg^{-1}·min^{-1}	PD-3 inhibitor				↑CO, ↓SVR, ↓PVR
Levosimendan	0.05–0.2 μg·kg^{-1}·min^{-1}	Myofilament Ca^{2+} sensitizer, PD-3 inhibitor				↑CO, ↓SVR, ↓PVR

Circulation. 2017;136:e232–e268



Stevenson, Circulation 2003;108:367-372

POSITIVE INOTROPES AND/OR VASOPRESSORS USED TO TREAT ACUTE HEART FAILURE

Vasodilator	Bolus	Infusion rate
Dobutamine[a]	No	2–20 µg/kg/min (beta+)
Dopamine	No	3–5 µg/kg/min; inotropic (beta+)
		>5 µg/kg/min: (beta+), vasopressor (alpha+)
Milrinone[a,b]	25–75 µg/kg over 10–20 min	0.375–0.75 µg/kg/min
Enoximone[a]	0.5–1.0 mg/kg over 5–10 min	5–20 µg/kg/min
Levosimendan[a]	12 µg/kg over 10 min (optional) [c]	0.1 µg/kg/min, which can be decreased to 0.05 or increased to 0.2 µg/kg/min
Norepinephrine	No	0.2–1.0 µg/kg/min
Epinephrine	Bolus: 1 mg can be given i.v. during resuscitation, repeated every 3–5 min	0.05–0.5 µg/kg/min


LTM
PulmoneticSystems
VIASYS
LTV 1200
SPRINT PACK
VIASYS

Noninvasive Ventilation in Acute Pulmonary Edema

Respiratory Benefits

-increases tidal volume
-unloads respiratory muscles
-decreases dead space ventilation



Hemodynamic Benefits
-alters cardiac transmural presures

-Decreases venous return (preload)

-decreases afterload

-no change or increase in cardiac index


Rationale of positive pressure ventilation in CPE
Positive Pressure
↑ ITP
↑ FRC
↓Pre-load
↓ Venous return
↓ LV afterload
↓ PTM
↑ PaO2
↓ WOB
↑ Cardiac performance
↓ pulmonary congestion

The management of patients with acute heart failure: *pharmacotherapy* (1)

Recommendations	Class	Level
Diuretics		
Intravenous loop diuretics are recommended for all patients with AHF admitted with signs/symptoms of fluid overload to improve symptoms. It is recommended to regularly monitor symptoms, urine output, renal function and electrolytes during use of i.v. diuretics.	I	C
In patients with new-onset AHF or those with chronic, decompensated HF not receiving oral diuretics the initial recommended dose should be 20–40 mg i.v. furosemide (or equivalent); for those on chronic diuretic therapy, initial i.v. dose should be at least equivalent to oral dose.	I	B
It is recommended to give diuretics either as intermittent boluses or as a continuous infusion, and the dose and duration should be adjusted according to patients' symptoms and clinical status.	I	B
Combination of loop diuretic with either thiazide-type diuretic or spironolactone may be considered in patients with resistant oedema or insufficient symptomatic response.	IIb	C

European Heart Journal (2016) **37**, 2129-2200 - doi:10.1093/eurheartj/ehw 128

The management of patients with acute heart failure: *pharmacotherapy* (2)

Recommendations	Class	Level
Vasodilators		
i.v. vasodilators should be considered for symptomatic relief in AHF with SBP >90 mmHg (and without symptomatic hypotension). Symptoms and blood pressure should be monitored frequently during administration of i.v. vasodilators.	**IIa**	**B**
In patients with hypertensive AHF, i.v. vasodilators should be considered as initial therapy to improve symptoms and reduce congestion.	**IIa**	**B**
Inotropic agents – dobutamine, dopamine, levosimendan, phosphodiesterase III (PDE III) inhibitors		
Short-term, i.v. infusion of inotropic agents may be considered in patients with hypotension (SBP <90 mmHg) and/or signs/symptoms of hypoperfusion despite adequate filling status, to increase cardiac, increase blood pressure, improve peripheral perfusion and maintain end-organ function.	**IIb**	**C**
An intravenous infusion of levosimendan or a PDE III inhibitor may be considered to reverse the effect of beta-blockade if beta-blockade is thought to be contributing to hypotension with subsequenthypoperfusion.	**IIb**	**C**
Inotropic agents are not recommended unless the patient is symptomatically hypotensive or hypoperfused because of safety concern.	**III**	**A**

European Heart Journal (2016) **37**, 2129-2200 - doi:10.1093/eurheartj/ehw 128

The management of patients with acute heart failure: *pharmacotherapy* (3)

Recommendations	Class	Level
Vasopressors		
A vasopressor (norepinephrine preferably) may be considered in patients who have cardiogenic shock, despite treatment with another inotrope, to increase blood pressure and vital organ perfusion.	IIb	B
It is recommended to monitor ECG and blood pressure when using inotropic agents and vasopressors, as they can cause arrhythmia, myocardial ischaemia, and in the case of levosimendan and PDE III inhibitors also hypotension	I	C
In such cases intra-arterial blood pressure measurement may be considered.	IIb	C
Thrombo-embolism prophylaxis		
Thrombo-embolism prophylaxis (e.g. with LMWH) is recommended in patients not already anticoagulated and with no contra-indication to anticoagulation, to reduce the risk of deep venous thrombosis and pulmonary embolism.	I	B
Other drugs		
For acute control of the ventricular rate in patients with atrial fibrillation:		
a. digoxin and/or beta-blockers should be considered as the first-line therapy;	IIa	C
b. amiodarone may be considered.	IIb	B
Opiates may be considered for cautious use to relieve dyspnoea and anxiety in patients with severe dyspnoea but nausea and hypopnea may occur.	IIb	B

European Heart Journal (2016) **37**, 2129-2200 - doi:10.1093/eurheartj/ehw 128

Regarding renal replacement therapy in patients with acute heart failure

Recommendations	Class	Level
Ultrafiltration may be considered for patients with refractory congestion, who failed to respond to diuretic-based strategies.	IIb	B
Renal replacement therapy should be considered in patients with refractory volume overload and acute kidney injury.	IIa	C

European Heart Journal (2016) **37**, 2129-2200 - doi:10.1093/eurheartj/ehw 128

Regarding oral evidence-based disease-modifying therapies in patients with acute heart failure

Recommendations	Class	Level
In case of worsening of chronic HFrEF, every attempt should be made to continue evidence-based, disease-modifying therapies, in the absence of haemodynamic instability or contra-indications.	I	C
In the case of de novo HFrEF, every attempt should be made to initiate these therapies after haemodynamic stabilization.	I	C

European Heart Journal (2016) **37**, 2129-2200 - doi:10.1093/eurheartj/ehw 128

Regarding management of patients with cardiogenic shock

Recommendations	Class	Level
In all patients with suspected cardiogenic shock, immediate ECG and echocardiography are recommended.	I	C
All patients with cardiogenic shock should be rapidly transferred to a tertiary care center which has a 24/7 service of cardiac catheterization, and a dedicated ICU/CCU with availability of short-term mechanical circulatory support.	I	C
In patients with cardiogenic shock complicating ACS an immediate coronary angiography is recommended (within 2 hours from hospital admission) with an intent to perform coronary revascularization.	I	C
Continous ECG and blood pressure monitoring are recommended.	I	C
Invasive monitoring with an arterial line is recommended.	I	C
Fluid challenge (saline or Ringer's lactate, >200 ml/15-30 min is recommended as the first-line treatment if there is no sign of overt fluid overload.	I	C
Intravenous inotropic agents (dobutamine) may be considered to increase cardiac output.	IIb	C
Vasopressors (norepinephrine preferable over dopamine) may be considered if there is a need to maintain SBP in the presence of persistent hypoperfusion.	IIb	B
IABP is not routinely recommended in cardiogenic shock.	III	B
Short-term mechanical circulatory support may be considered in refractory cardiogenic shock depending on patient age, co-morbidities and neurological function.	IIb	C

CIRCULATORY MECHANICAL SUPPORT






ΕΥΧΑΡΙΣΤΩ ΠΟΛΥ